NextCure (NXTC) Competitors $0.66 +0.05 (+7.43%) As of 10:36 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NXTC vs. HOWL, CELU, CNTX, RNXT, ANVS, PRLD, ADVM, ATNM, APLT, and STTKShould you be buying NextCure stock or one of its competitors? The main competitors of NextCure include Werewolf Therapeutics (HOWL), Celularity (CELU), Context Therapeutics (CNTX), RenovoRx (RNXT), Annovis Bio (ANVS), Prelude Therapeutics (PRLD), Adverum Biotechnologies (ADVM), Actinium Pharmaceuticals (ATNM), Applied Therapeutics (APLT), and Shattuck Labs (STTK). These companies are all part of the "pharmaceutical products" industry. NextCure vs. Its Competitors Werewolf Therapeutics Celularity Context Therapeutics RenovoRx Annovis Bio Prelude Therapeutics Adverum Biotechnologies Actinium Pharmaceuticals Applied Therapeutics Shattuck Labs Werewolf Therapeutics (NASDAQ:HOWL) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, community ranking, earnings, risk, institutional ownership, dividends and valuation. Which has more volatility & risk, HOWL or NXTC? Werewolf Therapeutics has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, NextCure has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Do analysts prefer HOWL or NXTC? Werewolf Therapeutics currently has a consensus price target of $8.33, indicating a potential upside of 548.51%. NextCure has a consensus price target of $3.50, indicating a potential upside of 429.50%. Given Werewolf Therapeutics' higher possible upside, equities research analysts clearly believe Werewolf Therapeutics is more favorable than NextCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Werewolf Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00NextCure 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in HOWL or NXTC? NextCure received 47 more outperform votes than Werewolf Therapeutics when rated by MarketBeat users. However, 68.63% of users gave Werewolf Therapeutics an outperform vote while only 65.08% of users gave NextCure an outperform vote. CompanyUnderperformOutperformWerewolf TherapeuticsOutperform Votes3568.63% Underperform Votes1631.37% NextCureOutperform Votes8265.08% Underperform Votes4434.92% Do institutionals & insiders have more ownership in HOWL or NXTC? 64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by insiders. Comparatively, 17.9% of NextCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has higher valuation and earnings, HOWL or NXTC? Werewolf Therapeutics has higher revenue and earnings than NextCure. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWerewolf Therapeutics$1.14M50.45-$37.37M-$1.67-0.77NextCureN/AN/A-$62.72M-$1.76-0.38 Does the media favor HOWL or NXTC? In the previous week, Werewolf Therapeutics had 1 more articles in the media than NextCure. MarketBeat recorded 3 mentions for Werewolf Therapeutics and 2 mentions for NextCure. Werewolf Therapeutics' average media sentiment score of 1.81 beat NextCure's score of 1.43 indicating that Werewolf Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Werewolf Therapeutics Very Positive NextCure Positive Is HOWL or NXTC more profitable? NextCure has a net margin of 0.00% compared to Werewolf Therapeutics' net margin of -578.80%. Werewolf Therapeutics' return on equity of -58.83% beat NextCure's return on equity.Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics-578.80% -58.83% -38.45% NextCure N/A -62.50%-53.67% SummaryWerewolf Therapeutics beats NextCure on 12 of the 16 factors compared between the two stocks. Get NextCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NXTC vs. The Competition Export to ExcelMetricNextCurePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.54M$6.91B$5.59B$8.59BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-0.328.8127.1220.00Price / SalesN/A254.61419.48155.53Price / CashN/A65.8538.2534.64Price / Book0.166.567.104.69Net Income-$62.72M$143.93M$3.23B$247.88M7 Day Performance33.40%3.35%2.45%2.34%1 Month Performance52.20%10.64%8.65%6.06%1 Year Performance-54.73%3.73%31.26%13.59% NextCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NXTCNextCure4.6675 of 5 stars$0.66+7.4%$3.50+429.5%-56.7%$18.54MN/A-0.3290Positive NewsShort Interest ↓HOWLWerewolf Therapeutics3.9512 of 5 stars$1.20-0.8%$8.33+594.4%-61.6%$53.85M$1.14M-0.7840Positive NewsGap UpCELUCelularity0.5434 of 5 stars$2.24+6.2%N/A-46.1%$53.65M$54.22M-0.85220News CoverageGap UpCNTXContext Therapeutics3.1065 of 5 stars$0.59+1.9%$6.00+920.4%-69.7%$52.75MN/A-0.657Positive NewsGap UpRNXTRenovoRx2.9753 of 5 stars$1.42+1.4%$7.00+393.0%+29.5%$51.93M$240K-2.496Short Interest ↓High Trading VolumeANVSAnnovis Bio2.1276 of 5 stars$2.63+11.9%$34.75+1,221.3%-58.5%$51.25MN/A-0.593News CoverageAnalyst ForecastAnalyst RevisionPRLDPrelude Therapeutics3.2522 of 5 stars$0.91+2.4%$4.00+341.0%-72.8%$51.22M$7M-0.51120Positive NewsGap UpADVMAdverum Biotechnologies3.9937 of 5 stars$2.43+9.5%$26.40+986.4%-64.6%$50.77M$1M-0.41190Short Interest ↑Gap UpATNMActinium Pharmaceuticals1.2333 of 5 stars$1.62+5.2%$4.00+146.9%N/A$50.54M$81K-1.1730APLTApplied Therapeutics4.29 of 5 stars$0.36+0.7%$6.10+1,614.0%-92.7%$50.39M$265K-0.2230STTKShattuck Labs2.5359 of 5 stars$1.05+3.5%$7.50+617.7%-84.0%$50.05M$4.61M-0.68100Positive News Related Companies and Tools Related Companies HOWL Competitors CELU Competitors CNTX Competitors RNXT Competitors ANVS Competitors PRLD Competitors ADVM Competitors ATNM Competitors APLT Competitors STTK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NXTC) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NextCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NextCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NXTC Stock Free NXTC Stock Alerts